IRVINE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the ...

Avacta Group plc, the developer of Affimer ® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global ...

ELISA kits have been integrated into many laboratory environments. Countless hours have been spent looking for ways to simplify the complex chemistry in these kits. Researchers are always ...

CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory ...

A desire for a simpler, cheaper way to do common laboratory tests for medical diagnoses and to avoid 'washing the dishes' led researchers to develop a new technology that reduces cost and time. The 3D ...

Enzyme linked immunosorbent assay (ELISA) is one of the most widely used laboratory disease diagnosis methods. However, performing ELISA in low-resource settings is limited by long incubation time, ...

Bringing automation on any scale into your lab can be an intimidating prospect, especially for new users. There can be significant benefits to automating a method or process, but there are also many ...

Avacta Group, a developer of Affimer biotherapeutics and reagents, announced that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the ...

Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus Avacta Group plc (AIM: AVCT), the developer of Affimer® ...